Earnings ·
Cogent Biosciences reports Q3 net loss of $111.4M and cash balance of $791.1M
COGTCogent Biosciences, Inc.
Cogent Biosciences reported a third-quarter 2026 net loss of $111.4 million, compared to an $80.9 million loss in the prior-year period. Research and development expenses rose to $75.1 million from $69.0 million, while general and administrative expenses increased significantly to $42.1 million from $14.4 million due to commercial readiness investments for bezuclastinib. The company ended the quarter with a cash balance of $791.1 million in cash, equivalents, and marketable securities, which management expects will fund operations into late 2028. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.